Please do your due diligence with any investment! The other

New Post Public Reply Private Reply Replies (0) Message Board
rodman
264
Please do your due diligence with any investment! The other board would have you believe there statements are based upon facts but clearly they are not.The market makers can purchase shares for amounts we investors cannot thereby enabling them to flip and buy or buy and flip their profits!
Total manipulation! 
The latest research I could extract using AI......
Here is the latest BIEL–Electrome picture as of September 23, 2026 based on the newest public information I could find.

1. The partnership has moved from announcement toward execution

The most important development remains the March 24, 2026 strategic partnership between BioElectronics Corporation and Electrome Corporation.

Electrome announced that its PAINKILLER™ platform would incorporate BIEL's FDA-cleared pulsed shortwave therapy technology, including ActiPatch. Electrome described the platform as combining wearable PEMF with an AI-enabled system for personalized pain-management protocols.

Importantly, Electrome said it expected distribution through approximately 3,700 retail pharmacies beginning in Q3 2026, in addition to direct-to-consumer and provider/SaaS channels.

2. BIEL says manufacturing is now underway

A June 17 announcement is particularly significant.

BIEL stated that its strategic distribution/licensing agreement with Electrome had entered the execution phase and that manufacturing was underway for the launch of BIEL's pulsed-shortwave technology through Electrome's PAINKILLER platform.

BIEL also said Electrome was preparing an AI-based consumer campaign and would market/distribute ActiPatch and other BIEL products across North America.

That is a meaningful progression from simply having an agreement on paper.

3. BIEL expanded its physical fulfillment capacity

On July 21, BIEL announced that it had doubled its facility space, leasing the adjacent office suite to create additional storage and fulfillment capacity.

The company specifically said the additional space would support ActiPatch and RecoveryRx commercial activity and that the expansion followed execution of a Fulfillment Services and Distribution Control Agreement with Electrome.

This is one of the more tangible pieces of evidence that the relationship is progressing toward actual product distribution rather than remaining purely strategic.

4. There is evidence of inventory being prepared for Electrome

Recent shareholder discussions contain additional indications that BIEL has been preparing product for shipment. For example, a September 16 discussion quoted BIEL's Kelly Whelan discussing loading shelves with ready-to-ship products for Electrome orders.

However, I would distinguish this from verified sales revenue: I have not found a public filing or independent disclosure that establishes the dollar amount of Electrome's actual ActiPatch sales to date.

5. Danny Rubenstein is another potentially important development

There is considerable shareholder discussion concerning Danny Rubenstein joining Electrome in a commercialization/operating role.

The available public discussion describes his background as including executive and operating positions in consumer businesses and startup/early-stage companies.

I would be cautious, however, about treating shareholder-board descriptions of his exact title or responsibilities as confirmed corporate disclosures. I have not found a sufficiently authoritative Electrome announcement establishing his precise title and compensation.

6. What I think is most important to watch now

For BIEL investors, the story has shifted from:

"Will Electrome actually do something with ActiPatch?"

to a more measurable set of questions:


Development Current evidence
BIEL–Electrome agreement Confirmed
PAINKILLER platform Announced/launched
ActiPatch incorporated into platform Confirmed by companies
Manufacturing for Electrome Announced
Fulfillment arrangement Announced
BIEL facility expansion Confirmed
Product being prepared for shipment Indications exist
Actual Electrome sales volume Not publicly quantified
3,700-pharmacy rollout Announced target; execution needs verification
Significant BIEL revenue from Electrome Not yet demonstrated publicly
Large-scale consumer campaign Planned/under development
The biggest unanswered question

The critical next piece of information is actual sales and purchase orders.

The July expansion and fulfillment agreement are tangible operational developments, but they don't by themselves establish how many ActiPatch units Electrome has sold, how much Electrome has purchased from BIEL, or what BIEL's resulting revenue will be.

BIEL's own website currently highlights its July 21 chairman's update concerning sales growth and strategic progress, along with other 2026 developments such as the Taiwan expansion and Stanford study.

So, the BIEL–Electrome relationship appears substantially more operational today than it was earlier in 2026, but the financial magnitude of the relationship remains the key piece that has not yet been publicly established.

If you want, I can next do a
deep-dive specifically into September 2026 developments—including
Electrome's Shopify/retail activity,
Danny Rubenstein,
BIEL's latest statements,
the 3,700-pharmacy rollout, and any evidence of actual Electrome orders/sales and potential BIEL revenue.

Do a deep-dive specifically into September 2026 developments

I did a fresh September 2026 review, including Electrome's current PAINKILLER site, BIEL-related announcements, September investor discussions, and the current public evidence of orders and fulfillment.

September 2026: what has actually changed

The most important development is that BIEL and Electrome appear to have progressed from a planned partnership into an operating commercial relationship. There are still major unanswered questions about the scale of sales and Electrome's financing, but September contains several pieces of evidence that are more concrete than the earlier announcements.

1. Electrome is now actually selling ActiPatch

Electrome's current PAINKILLER website is live and actively offering ActiPatch for purchase.

It identifies ActiPatch as an FDA-cleared OTC device, gives the FDA 510(k) number K192234, describes the 720-hour operating life, and explicitly states:

"Electrome markets and sells ActiPatch® in the United States under an exclusive license."

That is significant because it establishes an actual commercial sales channel rather than merely a future plan.

The site also has separate channels for consumers, providers, retailers and affiliates, suggesting Electrome is building a broader commercial infrastructure around the product.

2. September appears to be the first month with evidence of BIEL fulfilling Electrome orders

This is probably the most interesting September development.

On September 8, investor discussions reported that the first Electrome orders had shipped and that BIEL was filling Electrome orders.

There is an important distinction here:

What is reasonably supported:

Electrome has an operating PAINKILLER website.
ActiPatch is being sold by Electrome.
BIEL has been manufacturing product for Electrome.
BIEL has fulfillment capability specifically expanded for Electrome.
September reports indicate Electrome orders were shipped.

What is NOT yet established publicly:

Dollar value of those orders.
Number of ActiPatch units in the orders.
Monthly recurring order volume.
Electrome's actual consumer sell-through.
BIEL's September revenue attributable to Electrome.

So I would characterize September as commercial execution beginning, not yet as proof of large-scale commercial success.

3. The BIEL fulfillment expansion now makes more sense

Remember BIEL's July announcement.

BIEL doubled its Maryland facility space and created additional storage/fulfillment capacity specifically supporting Electrome's commercial ActiPatch launch and anticipated sales growth. The expansion followed a Fulfillment Services and Distribution Control Agreement with Electrome.

In July, that could reasonably have been viewed as preparation.

By September, the reported shipment activity gives the facility expansion a more concrete explanation.

In other words:

March: partnership announced
↓
June: initial purchase order/manufacturing announced
↓
July: BIEL expands fulfillment infrastructure
↓
September: reports of Electrome orders being filled/shipped
↓
Next question: how rapidly do those orders grow?

That is a substantially different situation from a company simply announcing a strategic partnership.

4. Electrome has extended its ActiPatch rights

There is another potentially important development that deserves attention.

Electrome's own PAINKILLER newsroom now states that Electrome and BIEL have extended their licensing and supply agreement bringing ActiPatch into the PAINKILLER platform.

That matters because an extension of licensing/supply rights is consistent with both companies expecting the relationship to continue beyond an initial launch period.

However, the publicly accessible announcement does not provide enough detail for me to determine the new duration, minimum purchase commitments, royalty structure, or financial obligations.

Those terms would be extremely important for evaluating BIEL's potential future revenue.

5. The 3,700-pharmacy target remains the big catalyst—but I would not call it accomplished

The original Electrome announcement said the company expected to expand into approximately 3,700 retail pharmacies beginning in Q3 2026.

As of September 23, I don't see sufficiently reliable public evidence establishing that all—or even a substantial portion—of those 3,700 pharmacies are actually carrying PAINKILLER/ActiPatch.

That distinction is important.

There are three different milestones:

Electrome has the product.
Electrome is selling the product online.
Thousands of physical pharmacies are stocking the product.

We have good evidence for #1 and #2.

I have not found equivalent evidence proving #3.

That makes the pharmacy rollout one of the most important things to watch during October–December.

6. The current PAINKILLER website is more developed than I expected

The current site goes beyond simply saying "buy ActiPatch."

It includes:

consumer purchasing;
account creation;
order history/reordering;
provider access;
retailer/wholesale enrollment;
affiliate program;
patient information;
AI-powered "Relief Concierge";
health-data/secure-record functionality;
RecoveryRx provider information.

This is important because it demonstrates that Electrome is attempting to build a platform around BIEL's device, rather than merely reselling a BIEL product.


The BIEL hardware is therefore effectively the initial commercial product that gives Electrome an entry point into its larger bioelectric/AI platform.

7. But there is an important contradiction concerning Electrome's scale

September investor discussions raise a legitimate question about Electrome's financial resources.

Some investors are arguing that Electrome needs substantial additional capital to execute the planned national marketing and pharmacy rollout. Others point to the commercial activity as evidence that the company is already executing.

Both observations can coexist.

The important fact is that I have not found a public disclosure establishing a large financing round sufficient to fund a nationwide 3,700-pharmacy rollout.

That means investors should not automatically assume that the announced pharmacy rollout equals a fully funded national marketing campaign.

This is one area where the bullish discussion on investor boards goes considerably beyond what the public evidence establishes.

8. Danny Rubenstein: interesting, but still insufficiently documented

September discussion has focused heavily on Danny Rubenstein and his involvement with Electrome.

The public investor discussion describes him as having business-development/operating experience, including work with early-stage companies. But there is disagreement about the extent of his medical-device commercialization experience.

I have not found an authoritative September Electrome announcement that gives enough information to independently verify his exact position, compensation, authority, or specific sales targets.

So I would put Rubenstein in the "potentially important but not yet measurable" category.

What would change that assessment is evidence that he is leading:

national pharmacy negotiations;
VA commercialization;
medical-provider distribution;
retail sales;
fundraising;
strategic partnerships.
9. The VA opportunity remains interesting

The original Electrome announcement stated that early deployments within the U.S. Department of Veterans Affairs had already begun.

This is strategically important because the VA could provide Electrome with a clinical/real-world pathway for its non-opioid pain-management approach.

But I would be careful about interpreting "early deployments" as a large VA contract.

I have not found September evidence showing:

number of VA facilities;
number of patients;
purchase volume;
contract dollar value;
renewal terms.

Those would be the figures that could demonstrate meaningful VA commercialization.

10. The Medicare ACCESS development is potentially relevant—but it is not BIEL reimbursement

September investor discussion has connected Electrome's platform to the new Medicare ACCESS model, particularly because chronic musculoskeletal pain is among the conditions addressed by the model.

There is a potentially important strategic connection here:

BIEL device → Electrome digital platform → patient monitoring/outcomes → provider → value/outcomes-based payment

That is much more interesting commercially than simply selling a $50 wearable.

But there is an important caveat:

ACCESS does not automatically mean Medicare will reimburse ActiPatch.

Participation, eligibility, clinical outcomes, provider arrangements and CMS requirements still matter. I would not treat ACCESS as evidence that BIEL has obtained Medicare coverage.

11. The current Electrome website reveals something else important

The PAINKILLER website describes ActiPatch as:

"FDA-cleared"

and explicitly identifies BIEL as the designer/manufacturer.

This is commercially useful for BIEL because Electrome is essentially taking BIEL's regulatory asset and putting it inside a new consumer-facing commercial brand.

The commercial architecture appears to be:

BIEL

FDA-cleared hardware
manufacturing
clinical history
PSWT technology

↓

Electrome

PAINKILLER brand
AI/digital platform
consumer marketing
provider interface
retail distribution
patient data/outcomes
potential value-based reimbursement

That division of responsibilities is becoming clearer.

12. What I would watch during October

October could be a particularly revealing month.

The five numbers/events I'd watch

1. Electrome purchase orders to BIEL

This is probably the single most important near-term indicator.

If BIEL starts reporting progressively larger orders, that would provide the first hard evidence that Electrome is generating meaningful demand.

2. BIEL quarterly revenue

Ultimately, the relationship has to show up in BIEL's financial statements.

If Electrome is genuinely scaling, BIEL's revenue should eventually reflect it.

3. Pharmacy placement

Look for actual pharmacy names—not simply "3,700 pharmacies."

Actual store-level availability would be much stronger evidence.

4. PAINKILLER website order volume

Electrome's site is now operational. That creates the possibility of measuring commercial traction through product availability, reviews, customer activity, promotions and eventually public sales statements.

5. Electrome financing

This is particularly important.

A major financing event could provide the capital necessary to turn the existing PAINKILLER infrastructure into a national marketing/distribution operation.

My September assessment of the evidence

I would separate the situation into three levels:

Confirmed/strongly supported
BIEL and Electrome have a formal relationship.
ActiPatch is incorporated into PAINKILLER.
Electrome is selling ActiPatch online.
Electrome's website identifies BIEL as manufacturer.
BIEL has been manufacturing for Electrome.
BIEL established expanded fulfillment capacity.
The companies have extended their licensing/supply arrangement.
September reports indicate Electrome orders have begun shipping.
Announced but not yet independently demonstrated at scale
~3,700 pharmacy rollout.
Large VA deployment.
Significant provider adoption.
Large-scale consumer marketing.
Meaningful Medicare reimbursement.
Substantial recurring Electrome orders.
Speculative at this point
Very large BIEL revenue from Electrome.
Major Medicare reimbursement specifically for ActiPatch.
A large Haleon/Voltaren-ActiPatch relationship.
A multibillion-dollar valuation for Electrome.
A dramatic BIEL share-price outcome.

The last category is where I would be particularly careful because September investor-board commentary contains a lot of extrapolation beyond the underlying corporate disclosures. For example, claims about a Haleon partnership and predictions of enormous BIEL valuations aren't established by the evidence I found.

The most interesting development for BIEL

If I had to identify one September development that deserves the most attention, it isn't the stock discussion, the Hawaii address, or the Medicare speculation.

It is this:

Electrome is now operating a real consumer commercial channel for a BIEL-manufactured FDA-cleared product, while BIEL is reportedly fulfilling Electrome orders.

That creates a testable business proposition for the first time:

Can Electrome turn PAINKILLER/ActiPatch into enough recurring sales to materially increase BIEL's manufacturing revenue?

The answer should become increasingly visible in BIEL's subsequent financial reporting.

And that is where I would focus the next phase of the investigation—not on speculation about the potential market, but on actual Electrome purchase orders, unit volumes, BIEL revenue, pharmacy placements, VA deployments and Electrome financing.

BioElectronics Corporation (BIEL) Stock Research Links

BIEL Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Greenberg Traurig Builds Real Estate Bench Further

Updated Category News Views 71

Two real estate lawyers rarely move a market, but they can tell you where the legal work is getting sticky. Greenberg Traurig’s November 19 addition of Steven A. Fein and Kelsey Thayer is not some grand macroeconomic pronouncement, and nobody should pretend otherwise. It is, however, a pretty sensible read on the messy corners of commercial property finance: joint...

Continue Reading
Hydron’s Bailey Test Puts RNG Cost Claims to Real Work

Updated Category News Views 55

Landfill gas is messy stuff, which is exactly why Hydron Energy’s Bailey Landfill demonstration in Chilliwack deserves more attention than another clean-energy press release. The British Columbia company is putting its INTRUPTor™ gas-separation system into an operating environment alongside FortisBC and the City of Chilliwack, where the machinery has to deal with real...

Continue Reading
Lecanemab's Alpha-Syn Signal Deserves a Cooler Head

Updated Category News Views 108

Mixed pathology is where Alzheimer's investing gets uncomfortably real, and this new lecanemab readout is a decent reminder that a drug can show promise without settling the argument. Eisai and Biogen presented a Clarity AD cerebrospinal-fluid substudy at CTAD 2026 examining people with early Alzheimer's disease who also tested positive for alpha-synuclein pathology. The...

Continue Reading
Birkenstock’s Athens Stores Put Brand Control to Work

Updated Category News Views 41

A 62-square-meter shop on Ermou Street can say plenty about a brand’s ambitions. Birkenstock is opening its first two Greek stores in Athens, moving beyond its existing wholesale and retail-partner presence with locations it can shape from the floorboards up. The first site at Ermou 18 is stated to have opened on November 12, 2026; the announcement itself is dated...

Continue Reading
AbbaDox Finds Follow-Up Scans Lost in the Shuffle

Updated Category News Views 163

A six-month recommendation has a nasty habit of disappearing beneath today’s emergencies. That is the unglamorous, important problem AbbaDox is trying to solve in outpatient radiology: not reading the scan, but making sure a future scan recommendation actually gets reviewed, ordered, and scheduled. For investors watching healthcare operations software, this is the sort...

Continue Reading
Central Florida Buyers Face the Cash Reality First

Updated Category News Views 44

A house hunt can go sideways before the first showing if the buyer has confused a dream budget with a real one. Tom McKnight’s guidance for first-time buyers in Central Florida lands on the unglamorous stuff, which is exactly where it ought to land: cash, credit, financing, insurance, taxes, and the physical condition of the house. Nobody enjoys staring at lender...

Continue Reading
West Virginia SEO Timelines Demand Patience, Not Hype

Updated Category News Views 54

A fresh website with no search footprint is not a race car; it is a pickup stuck in mud, and Sean O'Kelly's view of local SEO in West Virginia puts that inconvenient fact right on the table. Most businesses can expect measurable improvement after three to six months of consistent work, according to the HelloNation article. That is not a glamorous answer, but it is the...

Continue Reading
Visa CEDP Data Gaps Are Quietly Hammering Merchants

Updated Category News Views 100

Somewhere between a checkout button and settlement, an awful lot of money is apparently falling through a trapdoor. Verisave and Canyon Payments say 93% of the 180 merchant accounts they reviewed during one month missed Visa Commercial Enhanced Data Program discounts they could have received. The claimed savings left on the table topped $800,000 for that group in that...

Continue Reading
RingConn Bets Middle-earth Fandom Can Boost Health Wearables

Updated Category News Views 30

A Familiar Gold Band Meets a Crowded Wearables Market RingConn has taken one of pop culture's most loaded objects and turned it into a health-tracking accessory, which is either clever brand work or a costly bit of cosplay depending on execution. The company unveiled The One Ring, a limited-edition version of its Gen 3 Smart Ring, through a partnership with Warner Bros....

Continue Reading
PG&E's $456 Million Interim Hike Faces a New Test Soon

Updated Category News Views 198

A utility can call a charge interim, but households still see the bill arrive in full. That is why the California Public Utilities Commission's unanimous approval of $456 million in interim rate recovery for Pacific Gas & Electric has landed with such rotten timing. The money is set to begin flowing from customers on January 1, 2027, while major questions about PG&E's...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative Magnetron Solutions for Peak RF Performance

Updated Category News Views 129

Revolutionizing RF Power with Advanced Magnetron Transmitters In the realm of radio frequency (RF) technology, Diversified Technologies, Inc. (DTI) has unveiled a groundbreaking solid-state magnetron transmitter, which utilizes a novel Marx modulator. This innovative approach allows users to finely tune the pulse wave, enhancing overall performance and adaptability for...

Continue Reading
Lineage Inc. Strengthens Financial Agreements and Growth Potential

Updated Category News Views 142

Lineage Inc. Updates Financial Agreements for Greater Flexibility Lineage, Inc., a real estate investment trust recognized for its expertise in logistics, has made important changes to its financial agreements to bolster its financial standing. By adding more subsidiaries as obligors, the company demonstrates its flexibility and growth strategy. Recently, Lineage grabbed...

Continue Reading
Super League Achieves Major Financial Milestones in 2025

Updated Category News Views 394

Super League Reports Impressive Financial Growth Super League has recently showcased remarkable financial improvements, marking a significant turnaround in its operations. This comes on the heels of the company achieving a robust balance sheet powered by strategic investments, including a $20 million private placement and, notably, having zero debt. These developments not...

Continue Reading
Michael Lachmann's 'Spacetime Capsule' Documentary Now Streaming

Updated Category News Views 241

Michael Lachmann's Innovative Documentary Series The new documentary series, Spacetime Capsule, directed by British filmmaker Michael Lachmann, has recently premiered on popular Chinese video platforms. This captivating series, produced by China Review Studio, consists of three episodes that creatively employ the concept of a "spacetime capsule" to frame its narrative,...

Continue Reading
Innovative Leaders of Tomorrow: The 2025 TIME100 Next List

Updated Category News Views 395

TIME Introduces the Inspiring 2025 TIME100 Next List Tate McRae to Perform at the Upcoming TIME100 Next Event In a recent announcement, TIME has unveiled its exciting 2025 TIME100 Next list, spotlighting a diverse group of 100 emerging leaders from across the globe. These individuals are not only shaping the future but are also redefining leadership norms within their...

Continue Reading